Isotope JSC, official distributor of isotope products manufactured by ROSATOM’s enterprises, successfully delivered lutetium-177, (which was produced according to EU GMP standards), to Nuclear Medicine Department of Policlinico of Bari (Apulia, Italy) for quality evaluation. The activity was implemented within the scope of the Healthcare Memorandum of Understanding signed between Apulia Region and ROSATOM in November 2019.

At present, lutetium-177 is considered to be one of the most promising agents in oncology therapy. Radiopharmaceuticals based on lutetium-177 have already demonstrated excellent therapeutic performances in several applications such as with prostate cancer and gastro-entero-pancreatic neuroendocrine tumor treatment. Policlinico of Bari verified that the entire supply chain of lutetium-177 conformed to international quality and safety standards.